Thyrocare Technologies Releases Unaudited Quarterly Results for June 30, 2026; Profit Rises

Thyrocare Technologies Releases Unaudited Quarterly Results for June 30, 2026; Profit Rises​

Thyrocare Technologies Limited has released its Unaudited Financial Results for the quarter ended June 30, 2026. The company presented both standalone and consolidated results, which were reviewed by external auditors and approved by the Board of Directors on July 23, 2026.

The unaudited financial results provide insights into the operational performance across various segments and present a strong top-line showing for the quarter.

Standalone Financial Performance​

For the standalone segment, Thyrocare recorded Total Revenue of 229.17 Rs. Crores for the quarter ended June 30, 2026. This was compared to 214.39 Rs. Crores in the preceding quarter (March 31, 2026) and 182.85 Rs. Crores in the quarter ended June 30, 2025.

The company recorded Total Expenses of 162.54 Rs. Crores during this period. The resulting Profit for the Period stood at 50.17 Rs. Crores, translating to an Earnings Per Share (EPS) of 3.15* on a basic basis per share. The Total Comprehensive Income for the quarter was 50.65 Rs. Crores.

Consolidated Results and Segment Breakdown​

In the consolidated results, Thyrocare reported Total Revenue of 244.17 Rs. Crores for the period ended June 30, 2026. The company’s total expenses were recorded at 176.59 Rs. Crores, leading to a Profit for the Period of 51.33 Rs. Crores. Total comprehensive income stood at 51.72 Rs. Crores. The Basic Earnings Per Share (EPS) was reported at 3.23* per share.

The unaudited consolidated financial results reflect operations across multiple primary business segments, as determined by the Chief Operating Decision Maker: Diagnostic Testing Services, Imaging Services, and Others.

A summary of the segmented performance is available below:


The segment results before tax totaled 63.43 Rs. Crores, with the company recording a share of profit of associate at 0.71 Rs. Crores.

Review and Regulatory Updates​

Both the standalone and consolidated unaudited financial results were reviewed by Price Waterhouse Chartered Accountants LLP. The independent review concluded that nothing had come to their attention that suggested the statements were not prepared in all material respects in accordance with applicable accounting standards, nor that they contained any material misstatement.

The management provided additional notes regarding the operations during the quarter ended June 30, 2026. Among these details, the Holding Company forfeited 3,733 equity stock options granted to employees whose services had discontinued, and this forfeiture was added back into the available option pool. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors on July 23, 2026.

THYROCARE Stock Price Movement​

Today, shares of Thyrocare Technologies Limited surged in a post-market session, closing at ₹564.25 after gaining 3.67% on ₹20.00 from previous day’s close. The stock saw heavy activity during trading hours, with the company achieving an intraday high of ₹597.6 and volumes reaching 12.16 million shares.